# A Pioneer of Cardiothoracic Surgery — the Brazilian Northeast Heart Transplant Program

## TL;DR

This paper reviews the history of heart transplantation, highlighting key milestones and innovations that have advanced the field.

## Contribution

The paper emphasizes the role of the Brazilian Northeast Heart Transplant Program in advancing regional cardiac care and innovation.

## Key findings

- The Programa Nordeste de Transplante Cardíaco overcame logistical and financial barriers in Brazil.
- Xenotransplantation using genetically modified pig hearts in 2022 offers new solutions for donor shortages.
- Cyclosporine in 1983 revolutionized organ rejection management, leading to a resurgence in heart transplants.

## Abstract

This review highlights the pivotal milestones in the development of cardiac
transplantation and related techniques. Beginning with Alexis Carrel's
pioneering work on vascular anastomosis and organ preservation, the narrative
progresses through groundbreaking achievements such as John Gibbon's invention
of the heart-lung machine in 1953 and James Hardy's daring chimpanzee-to-human
heart transplant in 1964. The story culminates in Christiaan Barnard’s historic
human heart transplant in 1967 and Euryclides Zerbini's leadership in bringing
this innovation to Brazil in 1968. Key advancements include the development of
orthotopic heart transplantation techniques by Richard Lower and Norman Shumway
and the resurgence of heart transplants following the introduction of
cyclosporine in 1983, which revolutionized organ rejection management. The
collaborative Programa Nordeste de Transplante Cardíaco, initiated in
1986, exemplifies regional innovation in overcoming logistical and financial
barriers in Brazil. Recent progress, such as the first successful
xenotransplantation using a genetically modified pig heart in 2022, underscores
ongoing efforts to address donor shortages and improve transplant outcomes. This
narrative is a testament to human ingenuity and perseverance in offering
life-saving solutions to end-stage heart disease.